Goto, Norihiro
Westcott, Peter M. K. http://orcid.org/0000-0001-9436-4857
Goto, Saori http://orcid.org/0000-0001-7811-7397
Imada, Shinya
Taylor, Martin S. http://orcid.org/0000-0003-1560-9276
Eng, George
Braverman, Jonathan
Deshpande, Vikram
Jacks, Tyler http://orcid.org/0000-0001-5785-8911
Agudo, Judith http://orcid.org/0000-0002-3576-3169
Yilmaz, Ömer H. http://orcid.org/0000-0002-7577-4612
Article History
Received: 23 March 2023
Accepted: 30 January 2024
First Online: 28 February 2024
Competing interests
: Ö.H.Y. holds equity and is a scientific advisory board member in Ava Lifesciences and AI Proteins. Ö.H.Y. receives research support from Microbial Machines. Ö.H.Y. is a consultant for Nestle. T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific and a co-founder of Dragonfly Therapeutics and T2 Biosystems; serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech, and Skyhawk Therapeutics; and is president of Break Through Cancer. The laboratory of T.J. currently receives funding from Johnson & Johnson and The Lustgarten Foundation, but these funds did not support the research described in this manuscript. The other authors declare no competing interests.